AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02450253 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Neuropsychological tests
Description: Neuropsychological tests will be performed prior to pre IMP dose MRI scan \& then parallel V2 of the tests repeated 3-5 post IMP dose and before 2nd MRI scan.~Participants act as own controls as 1 IMP occasion will be placebo- 2nd IMP occasion will be active. 7-30 days apart
Study NCT02450253 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Neuropsychological tests
Description: Neuropsychological tests will be performed prior to pre IMP dose MRI scan \& then parallel V2 of the tests repeated 3-5 post IMP dose and before 2nd MRI scan.~Participants act as own controls as 1 IMP occasion will be placebo- 2nd IMP occasion will be active. 7-30 days apart
Study NCT02450253 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MRI Scan - Arterial Spin Labelling
Description: Pre and post IMP dose on 2 occasions to detect difference in blood flow in deep brain 4 MRI scans in total
Study NCT02450253 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: MRI Scan - Arterial Spin Labelling
Description: Pre and post IMP dose on 2 occasions to detect difference in blood flow in deep brain 4 MRI scans in total
Study NCT02362373 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: levonorgestrel IUS
Description: placement of levonorgestrel intrauterine system
Study NCT00064701 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus Modified Release (MR)
Description: The target range for whole blood tacrolimus trough concentrations was 7 to 16 ng/mL for days 0 through 90, and 5 to 15 ng/mL thereafter.
Study NCT00064701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: The target range for whole blood tacrolimus trough concentrations was the recommended trough concentration range for Prograf: 7 to 16 ng/mL for days 0 through 90 and 5 to 15 ng/mL thereafter.
Study NCT00064701 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclosporine microemulsion
Description: The target range for whole blood cyclosporine trough concentrations was 125 to 400 ng/mL for days 0 through 90, and 100 to 300 ng/mL thereafter.
Study NCT00064701 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mycophenolate mofetil
Description: Oral
Study NCT00064701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: Oral
Study NCT00002676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carmustine
Study NCT00002676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Study NCT00002676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Study NCT00002676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Study NCT00002676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Study NCT00002676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Study NCT04696770 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness
Description: Mindfulness techniques will be taught to the participants
Study NCT01804335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD5789 0.01% Cream
Description: CD5789 0.01% cream applied on the lesions once daily for twelve weeks.
Study NCT00002676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Study NCT00002676 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low-LET cobalt-60 gamma ray therapy
Study NCT00002676 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low-LET photon therapy
Study NCT01462513 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: L-BLP25
Description: Treatment: 930µg per treatment once weekly for 8 weeks, then at 6-week intervals during years 1 and 2.
Study NCT01462513 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Treatment: Placebo 930µg per treatment, once weekly for 8 weeks, then at 6-week intervals during years 1 and 2.
Study NCT00763893 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Cover key details of the intervention. Must be sufficiently detailed to distinguish between arms of a study (e.g., comparison of different dosages of drug) and/or among similar interventions (e.g., comparison of multiple implantable cardiac defibrillators). For example, interventions involving drugs may include dosage form, dosage, frequency and duration.
Study NCT00763893 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan
Description: 50 mg/day if \< weight 50 kg 100 mg/day if weight > 50 kg
Study NCT02464631 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sofosbuvir + Ribavirin 1
Study NCT02464631 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir + Ribavirin 2
Study NCT02464631 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir + Ribavirin 3
Study NCT01109381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GT08
Description: GT08 is the combination of omeprazole 40mg daily, lauric acid 150-300mg daily, NAC 1.2 - 2g daily
Study NCT01968785 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Dose 25 Gy
Description: Renal Denervation is performed using the Beta-Cath 3.5F to a deliver radiation dose 25 Gy to the renal artery.
Study NCT01968785 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Dose 50 Gy
Description: Renal Denervation is performed using the Beta-Cath 3.5F to a deliver radiation dose 50 Gy to the renal artery.
Study NCT03461861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGB101 220 mg
Description: AGB101 oral dose of 220 mg/day capsule, given as once-daily dosing.
Study NCT03461861 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo, oral capsule given once-daily.
Study NCT01765881 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: administration of Misoprostol 25 micrograms capsule by intravaginal route every 4 hours, up to 4 capsules
Study NCT01765881 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dinoprostone
Description: administration of one sustained released pessary of 10 milligrams by intravaginal route
Study NCT01405079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: Gefitinib 250 mg/day oral daily
Study NCT01405079 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinorelbine+Cisplatin
Description: Vinorelbine 25 mg/m2 intravenous infusion on day 1 and day 8, Cisplatin 75 mg/m2 on day 1 for 4 cycles
Study NCT01946009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cidofovir 1% cream's basis, 2gr, three times per week, during 4 weeks.
Study NCT04509063 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Information about hypothetical mammography screening without benefits
Description: We will present an online questionnaire with two types of information on the harms of screening. Then we will compare the prevalence of irrational decisions in the two arms.
Study NCT00387686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhBMP-2/CPM
Study NCT00387686 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rhBMP-2/CPM
Study NCT00387686 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: rhBMP-2/CPM
Study NCT04022954 — intervention group
Intervention type: DEVICE
Intervention: Catheter ablation
Description: Inquiry AFocusII Double Loop and Advisor HD Grid, Sensor Enabled
Study NCT02013154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DKN-01 150 mg
Description: Administered by IV infusion
Study NCT02013154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Administered by IV infusion
Study NCT02013154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered by IV infusion
Study NCT02013154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DKN-01 300 mg
Description: Administered by IV infusion
Study NCT00046566 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Soy protein-milk protein-carbohydrate
Description: 40 grams of soy protein per day for 8 weeks, 40 grams of milk protein per day for 8 weeks, and 40 grams of carbohydrate per day for 8 weeks
Study NCT00046566 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Milk protein-carbohydrate-soy protein
Description: 40 grams of milk protein per day for 8 weeks, 40 grams of carbohydrate per day for 8 weeks, 40 grams of soy protein per day for 8 weeks.
Study NCT00046566 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Carbohydrate-soy protein-milk protein
Description: 40 grams of carbohydrate per day for 8 weeks, 40 grams of soy protein per day for 8 weeks, 40 grams of milk protein per day for 8 weeks,
Study NCT01861951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Study NCT01861951 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Study NCT03826914 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: CardioFlex Q10
Description: CardioFlex Q10 is a cardiovascular health supplement developed to increase collagen production, repair connective tissues, and help the body metabolize fats and protein. CardioFlex Q10 contains high amounts of lysine, proline and vitamin C, which the body requires to produce connective tissue (collagen). CardioFlex Q10 also includes additional supporting nutrients such as vitamin E, selenium, bio flavonoids, Coenzyme Q10 (Ubiqionol) and magnesium. The ingredients in CardioFlex Q10 help regulate the body's production of cholesterol, strengthen the arteries and heart, and reverse oxidation.
Study NCT03826914 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Isocaloric maltodextrin placebo that looks and tastes identical to CardioFLex Q10
Study NCT01588080 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neurally Adjusted Ventilatory Assist (NAVA)
Description: Neurally adjusted ventilatory assist (NAVA), an adjunct that can only be used with the Servo-i ventilator, allows the patient to synchronize spontaneous respiratory effort with mechanical ventilation. NAVA uses the electromyographic signal of the diaphragm (Edi) to transmit this electrical activity back to the ventilator. The NAVA catheter is a functional gastric tube that has electrodes embedded within it and positioned at the level of diaphragm using an electrocardiogram signal. These electrodes continuously (every 5ms) detect the amplitude, duration, and frequency of the Edi and provide pressure support in proportion to this electrical activity. Proportionality is controlled by a NAVA factor (cmH20/microvolt) and is adjusted by the user.
Study NCT01588080 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: SiPAP - placebo
Description: The Infant Flow® SiPAP provides noninvasive support to neonates. CPAP and Biphasic modes are provided by the Infant Flow® SiPAP. CPAP is an elevated pressure (above atmospheric) and is used to increase a premature babies functional residual capacity (FRC). CPAP is a modality used for babies with both central apneas and mild/moderate increase work of breathing. CPAP increases the FRC and ultimately recruits collapsed alveoli and improves gas exchange in the lungs. BiPhasic, on the other hand, is a modality used for babies that require more respiratory support than CPAP can provide. In BiPhasic mode, respiratory rate (RR), inspiratory time (Ti), and peak inspiratory pressures (PIP) are set and not synchronized with the patients breathing efforts.
Study NCT02268318 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 2-Fermented dairy Product with No Phytosterols (control)
Description: 2-1 bottle of control product/day
Study NCT01936129 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Copaxone
Study NCT01936129 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (buffered normal saline w/v)
Study NCT04252378 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deep Serratus Anterior Plane Block
Description: Deep Serratus Anterior Plane Block was performed just before the start of surgery after anesthetic induction through ultrasound-guidance.
Study NCT04252378 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Superficial Serratus Anterior Plane Block
Description: Superficial Serratus Anterior Plane Block was performed just before the start of surgery after anesthetic induction through ultrasound-guidance.
Study NCT03147768 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Distal Pancreatectomy Sealing Using LTW
Description: The device's intended use is to seal the pancreatic surface using a laser to weld human albumin based biomaterials after surgical removal of pancreatic tumors during a partial pancreatectomy.
Study NCT03748381 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cataract surgery
Description: During cataract surgery patients will be implanted with the AT Zeiss Lisa tri in one eye and the Rayner trifocal in the contralateral eye
Study NCT04437303 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Continuation of oral anticoagulants
Description: Oral anticoagulant treatment will not be interrupted before the procedure.
Study NCT03004846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2981278 ointment
Description: GSK2981278 ointment will be applied topically twice daily for 8 weeks to all subjects in Part A and to randomized subjects in Part B. GSK2981278 will be a white to off-white ointment and a thin layer will be applied to all affected areas for given timeframe.~GSK2981278 is available as white to off-white ointment in unit strength 4% (w/w), 2% (w/w) and 0.8% (w/w), for topical application for application as thin layer to all affected areas .
Study NCT04437303 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interruption of oral anticoagulants
Description: Peri-operative interruption of oral anticoagulants will be according to the Dutch guideline on antithrombotic therapy.~* For direct oral anticoagulant users this will be in general 48 hours before the procedure, except for Dabigatran users with renal insufficiency: with estimated glomerular filtration rate 50-80 mL/min/1.73m\^2 72 hours and with estimated glomerular filtration rate 30-50 mL/min/1.73m\^2 96 hours before procedure.~* For vitamin K antagonist users this will be 5 days for phenprocoumon and 3 days for acenocoumarol.~* After the procedure oral anticoagulants will be resumed after 24 hours, if deemed safe by the treating physician.
Study NCT03413839 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physiotherapeutic Scoliosis Specific Exercises (PSSE)
Description: Exercises with emphasis on trunk extensor strengthening, and teaching patient better postural strategies in supine, sidelying, sitting, standing, and dynamic movements (walking, squatting), led by a PSSE-trained physical therapist.
Study NCT03413839 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Conventional Physical Therapy (PT)
Description: Conventional PT includes generalized pelvis, and trunk strengthening, lower extremity (LE) stretching, and use of modalities (ice and heat), iontophoresis and E-Stim.
Study NCT03868891 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EMST150
Description: The EMST150 consists of a handheld plastic tube with a mouthpiece on one end and an adjustable valve on the other end. Your child will close his/her lips around the mouthpiece and breathe out against resistance. The EMST150 will be adjusted to the point where airflow stops. Each day, your child will blow into the EMST150 5 sets of 5 times with a 10-15 second rest between each use and a 1-2 minute rest between each set of 5. You will adjust the resistance of the device each week, take a picture of the device settings, and document exercise sets performed in an exercise diary. These exercises will be performed twice in each nostril 2 times a day until your child's next visit at the MEPL (at least 8 weeks). Each session should take approximately 10-15 minutes, for a total of 30 minutes per day.
Study NCT02257658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycyline
Study NCT02257658 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Incentive
Study NCT01160796 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 1x14-day course of treatment during 4 cycles
Study NCT01160796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lcr35®
Description: 1x14-day course of treatment during 4 cycles
Study NCT03253510 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Poly-amide
Description: New denture base material that exhibit high flexibility, physical strength, heat and chemical resistance and the exceedingly rare allergy response
Study NCT03253510 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Poly-methyl methacrylate
Description: Gold standard denture base material
Study NCT00682500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calfactant
Description: Intratracheal Instillation of 0.5 mL/cm of height of 60 mg/mL suspension in two aliquots at study entry. Repeat dosing 12 hours later if criteria are met.
Study NCT00682500 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Room Air (placebo)
Description: Administration of 0.5 ml/cm height of air at study entry into the trachea. Repeat dosing at 12 hours if criteria are met
Study NCT02157623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levulan
Description: Levulan application followed by Red or Blue light PDT
Study NCT02157623 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Red Light PDT
Description: Aktilite™ (red lamp) after Levulan application on lesions
Study NCT02157623 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blue Light PDT
Description: Blu-U® (blue lamp) after Levulan application on lesions
Study NCT04129346 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fit2ThriveMB App
Description: The Fit2thriveMB app will encourage participants to increase their physical activity. Participants will be provided with educational information on physical activity and effective behavior change strategies for incorporating more physical activity into their daily lives to increase their step count. Participants will be prompted each morning to report the intensity of their symptom burden (0 to 10). Based on their symptom rating and their previous day's step counts, participants will be provided with three different options or levels of goals for that day to either increase or decrease 10-20% or remain constant.
Study NCT04129346 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fitbit
Description: The Fitbit measures PA intensity, steps, and heart rate and syncs directly with the smartphone and will automatically sync with the Fit2ThriveMB app and provide Fitbit data to the study team in real-time.
Study NCT04129346 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity Coaching Calls
Description: Participants will receive weekly coaching calls which will: a) provide feedback on the previous week's symptom burden and progress on PA goals; b) review personalized goals and strategies for increasing PA for the next week; c) provide instruction on effective behavioral change techniques
Study NCT00684268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silibinin
Description: comparison of different dosing schedule of Silibinin infusions (20 mg/kg/d infused over 2 hours) A: 3x5days B: 14 days C: 21 days D: 28 days~sequential the infusion duration will be shortened - 2 hours, then 1 hr and then 1/2 hr/infusion
Study NCT00684268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silibinin
Description: 20 mg/kg Silibinin iv /d /21 days, antiviral combination therapy will be continued
Study NCT04129346 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Living Coaching Calls
Description: Participants will receive weekly calls that will cover health and well-being topics for instance: symptom and stress management, healthy diet, hydration, sun safety, sleep hygiene, and meditation.
Study NCT04129346 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cancer.net app
Description: Cancer.net app content includes information about health and well-being, treatment guidelines specific to cancer type, symptom tracking and medication tracking
Study NCT01093053 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mind-Body Skills Groups
Description: The mind-body skills group program teaches participants how to do meditation, guided imagery, breathing techniques, and biofeedback. These mind-body techniques are taught and practiced in small groups of 8 to 10 people and also contain an element of social support.
Study NCT00709592 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Thymoglobulin
Description: Patients eligible for participation in this study will be randomized between receiving rabbit ATG for 3 days. Thymoglobulin will be administered according to VCU BMT standard of care starting day -9 and continued daily through day -7.
Study NCT00709592 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo TBI